Spero Therapeutics Inc. (SPRO)
NASDAQ · Healthcare
Spero Therapeutics Inc. EBITDA 2016–2025
Spero Therapeutics Inc. annual/quarterly ebitda history and growth rate from 2016 to 2024. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Spero Therapeutics Inc. ebitda for the quarter ending March 31, 2024 was -14.0 M, a 0.94% decrease year-over-year.
- Spero Therapeutics Inc. ebitda for the twelve months ending March 31, 2024 was -77.4 M.
- Spero Therapeutics Inc. annual ebitda for 2025 was 6.3 M, a 108.61% decrease from 2024.
- Spero Therapeutics Inc. annual ebitda for 2024 was -73.4 M, a 435.77% decrease from 2023.
- Spero Therapeutics Inc. annual ebitda for 2023 was 21.8 M, a 152.86% decrease from 2022.
- Spero Therapeutics Inc. annual ebitda for 2022 was -41.3 M.
EBITDA
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Spero Therapeutics Inc. EBITDA — FAQ
Spero Therapeutics Inc. (SPRO) ebitda over the last 10 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see SPRO's ebitda history?
The chart and table above show Spero Therapeutics Inc.'s ebitda by year and by quarter, including the growth rate.